Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 7/20 | 0.56 |
| ▸ | MMP9 | P14780 | 6/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | MMP3 | P08254 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10419474 | 1.00 | MMP2 (0.56) | MMP2MMP9LMNAHTTCYP2D6 | |
| SCHEMBL10420484 | 1.00 | MMP2 (0.56) | MMP2MMP9LMNAHTTCYP2D6 | |
| SCHEMBL10419952 | 1.00 | MMP2 (0.56) | MMP2MMP9LMNAHTTCYP2D6 | |
| SCHEMBL10419184 | 0.99 | MMP2 (0.57) | MMP2MMP9LMNAHTTCYP2D6 | |
| SCHEMBL10419216 | 0.95 | MMP2 (0.59) | MMP2MMP9LMNAHTTCYP2D6 | |
| SCHEMBL10420790 | 0.94 | MMP2 (0.50) | MMP2MMP9KMT2ACNR2ALDH1A1 | |
| SCHEMBL10419718 | 0.94 | MMP2 (0.50) | MMP2MMP9KMT2ACNR2ALDH1A1 | |
| SCHEMBL10419243 | 0.94 | MMP2 (0.50) | MMP2MMP9KMT2ACNR2ALDH1A1 | |
| SCHEMBL10419942 | 0.94 | MMP2 (0.59) | MMP2MMP9ALDH1A1GAAPPARA | |
| SCHEMBL10420376 | 0.92 | MMP2 (0.51) | MMP2MMP9CYP2C9CYP2C19KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109715637-B | Glucokinase activators and methods of use thereof | 百时美施贵宝公司 | 2022-04-05 | — | — | CN | disclosed |
| US-10604541-B2 | Glucokinase activators and methods of using same | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-03-31 | — | — | US | disclosed |
| US-20190233449-A1 | GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-08-01 | — | — | US | disclosed |
| EP-3487862-A1 | GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | Bristol-Myers Squibb Company (US) | 2019-05-29 | — | — | EP | disclosed |
| WO-2018017910-A1 | GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-01-25 | — | — | WO | disclosed |
| EP-2850073-B1 | PYRIMIDINYLPIPERIDINYLOXYPYRIDONE ANALOGUES AS GPR119 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2017-07-19 | — | — | EP | disclosed |
| US-9174965-B2 | Pyrimidinylpiperidinyloxypyridone analogues as GPR119 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-11-03 | — | — | US | disclosed |
| EP-2566862-B1 | BENZOFURANYL ANALOGUES AS GPR119 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2015-09-16 | — | — | EP | disclosed |
| US-9062028-B2 | Bicyclic nitrogen containing heteroaryl TGR5 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-06-23 | — | — | US | disclosed |
| US-20150133479-A1 | PYRIMIDINYLPIPERIDINYLOXYPYRIDONE ANALOGUES AS GPR119 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-05-14 | — | — | US | disclosed |
| US-20090042919-A1 | METHOD FOR MODULATING GPR119 G PROTEIN-COUPLED RECEPTOR AND SELECTED COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2009-02-12 | — | — | US | disclosed |
| US-20090023702-A1 | PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2009-01-22 | — | — | US | disclosed |
| WO-2009012277-A1 | METHOD FOR MODULATING GPR119 G PROTEIN-COUPLED RECEPTOR AND SELECTED COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-01-22 | — | — | WO | disclosed |
| WO-2009012275-A1 | PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-01-22 | — | — | WO | disclosed |
| WO-2008137435-A1 | [6,6] AND [6,7]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-13 | — | — | WO | disclosed |
| WO-2008137436-A1 | [6,5]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-13 | — | — | WO | disclosed |
| US-4933367-A | Carboxylic acid derivatives, processes for the preparation thereof, the use thereof, and pharmaceutical compositions which contain these compounds | BOEHRINGER MANNHEIM GMBH (DE) | 1990-06-12 | — | — | US | disclosed |
| EP-0226636-B1 | NEW CARBOXYLIC ACID DERIVATIVES, THEIR MANUFACTURING PROCESS, USE AND MEDICINES CONTAINING THESE COMPOUNDS | Roche Diagnostics GmbH (DE) | 1989-02-08 | — | — | EP | disclosed |
| EP-0226636-A1 | NEW CARBOXYLIC ACID DERIVATIVES, THEIR MANUFACTURING PROCESS, USE AND MEDICINES CONTAINING THESE COMPOUNDS. | BOEHRINGER MANNHEIM GMBH (DE) | 1987-07-01 | — | — | EP | disclosed |
| WO-1987000521-A2 | NEW CARBOXYLIC ACID DERIVATIVES, THEIR MANUFACTURING PROCESS, USE AND MEDICINES CONTAINING THESE COMPOUNDS | BOEHRINGER MANNHEIM GMBH (DE) | 1987-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10604541-B2 | Glucokinase activators and methods of using same | GCK, GCKR, GALK1 | MMP2 300/4885MMP9 614/4885LMNA 3749/4885 |
| US-20150133479-A1 | PYRIMIDINYLPIPERIDINYLOXYPYRIDONE ANALOGUES AS GPR119 MODULATORS | GPR119, GPR180, GPR139 | MMP2 4676/4885MMP9 3566/4885LMNA 4490/4885 |
| US-20090042919-A1 | METHOD FOR MODULATING GPR119 G PROTEIN-COUPLED RECEPTOR AND SELECTED COMPOUNDS | GPR119, GPR65, GPR84 | MMP2 3934/4885MMP9 3749/4885LMNA 4695/4885 |
| US-20190233449-A1 | GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | GCK, GCKR, GALK1 | MMP2 300/4885MMP9 614/4885LMNA 3749/4885 |
| US-20090023702-A1 | PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | GPR119, GPR65, GPR27 | MMP2 4524/4885MMP9 4289/4885LMNA 3618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.